Ignite Creation Date:
2024-05-06 @ 4:34 PM
Last Modification Date:
2024-10-26 @ 2:12 PM
Study NCT ID:
NCT05028348
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-07-03
First Post:
2021-08-25
Brief Title:
A Study of Combination of Selinexor Pomalidomide and Dexamethasone SPd Versus Elotuzumab Pomalidomide and Dexamethasone EloPd in Subject With Previously Treated Multiple Myeloma
Sponsor:
Stichting European Myeloma Network
Organization:
Stichting European Myeloma Network
Study Overview
Official Title:
A Phase 3 Randomized Open-label Trial of Selinexor Pomalidomide and Dexamethasone SPd Versus Elotuzumab Pomalidomide and Dexamethasone EloPd in Patients With Relapsed or Refractory Multiple Myeloma RRMM
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This phase 3 randomized open-label multicenter trial will compare the efficacy safety and the impact on health-related quality of life HR-QoL of SPd versus EloPd in pomalidomide-naïve patients with MM who have received 1 to 4 prior anti-MM regimens and been treated with an immunomodulatory imide drug IMiD proteasome inhibitor PI and an anti-CD38 monoclonal antibody mAb
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None